EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Randomized controlled diagnostic trial to assess dRAST time to result and its utility for antimicrobial stewardship recommendation in bacteremic patients

Ana Verónica Halperin iD, Rosa Escudero iD, María García-Castillo, María José Cardenas-Isasi, Francesca Gioia, Javier Cobo, Ana María Sánchez-Díaz iD, Rafael Cantón iD

Microbiology Spectrum · 07.10.2025 · 13 (10)

DOI: 10.1128/spectrum.00288-25 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Microbiology Spectrum, erschienen am 07.10.2025. Verfasst von Ana Verónica Halperin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Microbiología, Hospital Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain. Hauptthemen laut MEDLINE: Antimicrobial Stewardship, Bacteremia, Anti-Bacterial Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bloodstream infections cause great mortality and morbidity. Real-time microbiological information has been shown to have an impact on prognosis when combined with an antimicrobial stewardship (AMS) program. dRAST is a rapid commercial antimicrobial susceptibility testing (AST) system based on real-time microscopy. The primary outcome of this trial was to compare positive blood culture’s time-to-result (TTR), defined as time from Gram stain to AST report, between dRAST and our standard of care in a real-life clinical setting. Secondary outcomes included microbiological concordance, time to antimicrobial stewardship recommendation (TAMS), and time to change antimicrobial prescription (TCAP) in agreement with AMS recommendation. We performed a prospective, open-label, randomized (1:1) diagnostic clinical trial comparing dRAST and our standard of care commercial MicroScan broth microdilution (MBMD) (MicroScan-Walkaway, Beckman-Coulter, USA) in 277 hospitalized patients with bacteremia. Categorical and continuous variables were compared by chi-squared and Mann-Whitney U tests, respectively. Median TTR, TAMS, and TCAP were 25, 28, and 29 hours in the MBMD group, and 9, 11, and 13 hours in the dRAST group, respectively. For gram-negative bacilli, essential agreement (EA) was 93.6%, categorical agreement (CA) 93.2%, very major error (VME) 14%, major error (ME) 3%, and minor error (mE) 1.4%. For gram-positive cocci, EA was 93.7%, CA 92.8%, VME 0%, ME 7.6%, and mE 1.8%. dRAST is a reliable method for guiding an antimicrobial stewardship program for bacteremia, allowing significant reductions in TTR, TAMS, and TCAP that might impact patient management and clinical outcomes. IMPORTANCE This study addresses a critical challenge in infectious diseases management by evaluating the efficacy of the dRAST system, a rapid antimicrobial susceptibility testing method, in guiding antimicrobial stewardship programs for patients with bloodstream infections. A randomized diagnostic trial was designed to address this objective. Our findings show that the use of dRAST significantly reduces time-to-result, time to antimicrobial stewardship recommendations, and time to appropriate therapy changes, particularly in critically ill patients. These results underline the potential of rapid diagnostic technologies to optimize patient outcomes and enhance antimicrobial stewardship efforts in real-world clinical settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antimicrobial StewardshipBacteremiaAnti-Bacterial AgentsHumansMaleFemaleProspective StudiesMiddle AgedMicrobial Sensitivity TestsAgedBlood CultureTime FactorsAdultAged, 80 and over

Stichwörter der Autor:innen

antimicrobial stewardshipbacteremiablood culturerapid ASTrapid tests

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Servicio de Microbiología, Hospital Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
  • Servicio de Enfermedades Infecciosas, Hospital Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
  • Service de Microbiología, Araba University Hospital, Osakidetza Basque Health Service, Vitoria-Gasteiz, Spain.
  • CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto Salud Carlos III (ISCIII), Madrid, Spain.

ORCID-Profile: Ana Verónica Halperin, Rosa Escudero, Ana María Sánchez-Díaz, Rafael Cantón

Zitieren

APA

Halperin, A. V., Escudero, R., García-Castillo, M., Cardenas-Isasi, M. J., Gioia, F., Cobo, J., Sánchez-Díaz, A. M., & Cantón, R. (2025). Randomized controlled diagnostic trial to assess dRAST time to result and its utility for antimicrobial stewardship recommendation in bacteremic patients. Microbiology Spectrum, 13(10). https://doi.org/10.1128/spectrum.00288-25

Vancouver

Halperin AV, Escudero R, García-Castillo M, Cardenas-Isasi MJ, Gioia F, Cobo J, et al. Randomized controlled diagnostic trial to assess dRAST time to result and its utility for antimicrobial stewardship recommendation in bacteremic patients. Microbiology Spectrum. 2025;13(10). doi:10.1128/spectrum.00288-25

BibTeX
@article{Halperin2025,
  author = {Halperin, Ana Verónica and Escudero, Rosa and García-Castillo, María and Cardenas-Isasi, María José and Gioia, Francesca and Cobo, Javier and Sánchez-Díaz, Ana María and Cantón, Rafael},
  title = {Randomized controlled diagnostic trial to assess dRAST time to result and its utility for antimicrobial stewardship recommendation in bacteremic patients},
  journal = {Microbiology Spectrum},
  year = {2025},
  volume = {13},
  number = {10},
  doi = {10.1128/spectrum.00288-25}
}
Kostenlos starten →